BioSpace

UniQure snags May Day decision date for Huntington’s gene therapy after arduous year

After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec for priority review, with a May 1 action date. If approved, the therapy—also called AMT-130—would be the first disease-modifying treatment for Huntington’s disease.

By BioSpace

1 min read
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights